Acumen 2024 net loss $102.3M; cash $231.5M; ALTITUDE-AD enrollment complete

Acumen Pharmaceuticals, Inc.

Net loss $102.3M vs $52.4M in 2023; R&D spend $93.8M (up 122%) driven by ALTITUDE-AD trial.
Cash, equivalents and marketable securities $231.5M, down from $306.1M; runway into H1 2027.
Phase 2 ALTITUDE-AD enrolled 542 early AD patients; topline results expected late 2026.
Phase 1 subcutaneous sabirnetug showed mild injection-site reactions; supports further SC development.
JPAD published Phase 1 INTERCEPT-AD results; sabirnetug well-tolerated with dose-dependent target engagement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.